RANIBIZUMAB MONOTHERAPY VERSUS COMBINED RANIBIZUMAB PLUS TRIAMCINOLONE FOR TREATING DIABETIC MACULAR EDEMA; EVALUATION AFTER SINGLE INJECTION
Basrah Journal of Surgery,
Volume 21, Issue 2, Pages 43-49
Anti vascular endothelial growth factor (Anti-VEGF) have been proved to be the main treatment for DME and also steroids showed a significant role in resolution of diabetic macular edema(DME). Based on concept of multifactorial causes of DME, this study proposed theoretically an adjuvant effects for steroids in combination with anti-VEGF for DME, the multifactorial complex pathogenetic mechanisms require a comprehensive approach.
This study compares the outcome of monotherapy of intravitreal Ranibizumab injection in one eye versus combined therapy of Ranibizumab+Triamcinolone in other eye of the same patient.
This study includes prospective consecutive interventional case series study. Patients with bilateral diabetic macular edema given Lucentis dose was 0.05 ml = 0.5 mg in on eye and Triamcinolone 0.05 ml = 2 mg in the other eye.
Thirty patients with bilateral diabetic macular edema were enrolled in this study, all have perfused macula. The mean age at the start of the study was 54 years.
The study has shown a promising results for the treating diabetic macular edema with combined therapy of Ranibizumab and Triamcinolone
- Article View: 156
- PDF Download: 119